Gmax Biopharm holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102, GMA105, and GMA301A/B drugs to be launched between 2023-2025, upon approval of respective clinical trials.
December 15, 2020
· 2 min read